| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 674.73 | 3.7% | 8.1% |
| Total Income | 682.53 | 3.4% | 8.8% |
| Expenditure | 790.91 | 13.1% | 16.2% |
| PBT | -108.38 | 1650.5% | 260.6% |
| Net Profit | -82.76 | 2804.6% | 265.8% |
| OPM | -12.56% | 17.09pp | 21.89pp |
| NPM | -12.13% | 12.56pp | 18.80pp |
| EPS | -6.84 | 2054.3% | 263.6% |
Profit collapse from legacy costs; H2 recovery hopes rest on geopolitical stabilization
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Prior guidance was vague (no specific FY27 targets); softer execution confirmed on Roha (25% utilization) and Consumer Products (still loss-making). Management met Q2 revenue guidance implicitly but missed on profitability due to legacy costs.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Ion Exchange faces a bifurcated story: legacy contract overruns and geopolitical headwinds crushed Q2 profits (-265.8% YoY PAT), but Industrial Products is growing strongly (+35% YoY) and a robust ₹296.9 Cr order book offers H2 recovery hopes. However, execution risk is high—Treatment Solutions needs geopolitical stabilization and order conversion, Specialty Chemicals requires successful pricing pass-through amid West Asia crisis, and Consumer Products must prove its breakeven path. Valuation likely to remain under pressure until H2 demonstrates recovery.
₹674.7 Cr
Revenue · −8.1% YoY₹-82.8 Cr
Reported PAT · −265.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Legacy project cost overruns fully accounted for Q2
METTreatment Solutions EBIT loss ₹121.5 Cr (vs ₹12.2 Cr loss prior year); mgmt says ~90% of negative PBT from legacy contracts
Strong order book ₹296.9 Cr will drive H2 recovery
OVERSTATEDOrder book real but treatment solutions revenue halved YoY; execution weak despite pipeline; H2 uplift requires geopolitical stabilization
Roha plant at 25% utilization, ramp-up progressing
MET25% achieved in Q2 but management acknowledged softer than expected; backward integration in final commissioning phase
Consumer Products on track for FY27 breakeven
OVERSTATEDH1 still showing ₹4.5 Cr EBIT loss despite 32% revenue growth; mgmt says marginally below expectations but projects end-FY27 breakeven
Industrial Products momentum will continue
METQ2 +35% YoY (₹136 Cr vs ₹100.9 Cr), H1 +25% YoY; strong tailwind from order inflows; EBIT at ₹86 Cr
Earnings quality
What changed since the last call
Treatment Solutions revenue collapsed
DowngradeQ2 revenue ₹149.8 Cr vs ₹295.8 Cr prior year (-49%); legacy contract cost overruns, geopolitical deferral, and revenue reversal on accounting matches all contributed.
Roha plant now operational but soft ramp
DowngradeCommissioned Sept 2025, now running at ~25% utilization (vs prior hope for faster ramp). Facility cost and West Asia input inflation weighing heavily; ~7% of specialty chem margin compression attributed here.
Industrial Products strong momentum
UpgradeQ2 +35% YoY (₹136 Cr), H1 +25% (₹241 Cr); EBIT at ₹86 Cr (vs ₹74 Cr). Order inflow of ₹81.3 Cr in Q2 driven by medium-sized and Hyundai deal. Segment expected to maintain growth.
Consumer Products still unprofitable
DowngradeH1 EBIT loss ₹4.5 Cr despite 32% revenue growth (₹212.9 Cr). Mgmt says marginally below expectations but still targeting FY27 end breakeven—appears optimistic.
Specialty Chemicals pricing pass-through in progress
NeutralRevenue +17% YoY but EBIT only ₹22.5 Cr; cost inflation from West Asia not yet fully passed through. Mgmt says domestic market seeing better acceptance, international slower.
The Q&A
Analysts probed hard on legacy cost quantum, Roha timeline, Hyundai contract specifics, and Consumer Products path to profitability. Management defended but hedged on contract-level margins, Hyundai FY27 revenue (would not quantify), and provided vague timelines on backward integration.
Specialty Chemicals margin drivers — Prathamesh Sawant, Abakkus Investment Managers
AnsweredRoha facility ~7% impact at segment level; West Asia crisis 7-8%; remainder from exchange gain. Mgmt says still in price pass-through phase, expects recovery.
Treatment Solutions cost overrun — Pratik Kothari, Unique PMS
AnsweredLegacy contracts expected cost overrun fully in Q2 numbers; been discussing for ~8 quarters; we've reached the bottom. No further material impact expected.
Roha backward integration completion — Deepak, Sundaram Mutual Fund
PartialFinal phase of commissioning ongoing. Should be completed within this financial year. Once done, will see favorable impact on profitability.
Hyundai contract FY27 revenue — Deepak, Sundaram Mutual Fund
DodgedWill not quantify specific contract revenue. Project is progressing; we expect a portion of revenue in FY27. Most execution planned for H2 per contractual terms.
Consumer Products breakeven timeline — Homiar Irani, independent investor
PartialPlan is to reach break-even by end of FY27. H1 was marginally below but our assessment is division should move towards break-even by year-end.
Government receivables and Jal Jeevan exposure — Gaurav Patel, individual investor
AnsweredJal Jeevan is less than 10% of overall receivables. Most backlog is industrial-side. Fund flow improving but calibrating dispatch in proportion to funds received.
Guidance
No specific FY27 consolidated revenue target stated
LowPrior call guidance was vague; implies conservative posture. Management focusing on segment-level execution (Treatment Solutions recovery, Industrial growth, breakeven targets).
Specialty Chemicals: expect improvement as Roha ramp-up progresses and pricing gains traction
MediumCurrently compressed 18% at segment level due to facility cost and input inflation. Mgmt expects single-digit margin recovery by end of year.
Treatment Solutions: return to 'average margin' in H2 with legacy contracts behind
MediumCurrently deeply loss-making; mgmt implies positive EBIT in H2 once order book executes and legacy overrun is past.
Consumer Products: reach breakeven by end of FY27
LowH1 still loss-making (-₹4.5 Cr EBIT) despite 32% growth. Target is aspirational given trajectory; mgmt says marginally below expectations.
CWIP balance ₹240 Cr as of Sept 2026; major investments in Roha backward integration, Ankleswar expansion, membrane UF facility Goa
HighRoha backward integration expected complete by FY27 end. Goa membrane expansion tied to Mann & Hummel partnership (commissioning targeted FY27 end).
Risks the call surfaced
Legacy contract overruns (Treatment Solutions)
HighCost overruns on legacy projects estimated at ~₹100 Cr, impacting Q2 by ~₹82.8 Cr net loss. While mgmt claims bottom reached, further adverse impacts could arise during final execution phases.
Geopolitical and macro headwinds
HighWest Asia crisis raising specialty chemical input costs (7-8% margin drag). Middle East dispatches being deferred due to geopolitical tensions, impacting Treatment Solutions H2 uplift expectations. Further escalation could delay more orders.
Roha facility ramp-up execution
HighRoha plant commissioned Sept 2025, running at ~25% utilization in Q2. Backward integration still in commissioning phase. Facility cost and input inflation both dragging margins. If ramp-up slows further, recovery timeline extends.
Execution risk on Treatment Solutions order book conversion
HighTreatment Solutions has strong order backlog of ₹296.9 Cr total (₹3,000 Cr industrial portion), but execution in first half was weak (revenue fell 49% YoY). Management expects significant H2 ramp, but geopolitical delays and contract complexity introduce execution risk.
Consumer Products profitability risk
MediumConsumer Products grew 30% YoY in Q2 but still unprofitable (-₹4.1 Cr EBIT). H1 loss ₹4.5 Cr. Mgmt's target of FY27 end breakeven is based on aspirational projections; actual execution may fall short.
Government receivables and fund flow risk
Medium~10% of receivables tied to Jal Jeevan Mission contracts. Fund flow has been slower than expected, forcing company to calibrate dispatch in proportion to funds received. Further delays could impact liquidity.
Management
Score 6/10. Transparent on headwinds (legacy costs, geopolitical risk, input inflation) but defensive on specifics (Hyundai contract FY27 revenue, Consumer Products margin path, contract-level profitability). Hedged timeline estimates. Mixed track record: Industrial Products delivering (+35% YoY), Specialty Chemicals growing (+17%) but margin-compressed, Consumer Products growing but still unprofitable. Treatment Solutions collapsed due to legacy cost misestimates, suggesting planning/estimation issues.
1 · Q3 FY27 (Oct-Dec 2026)
Treatment Solutions H2 execution ramp; Hyundai contract USD 52.83 Cr begins delivery phase
2 · Q3-Q4 FY27
Roha facility backward integration completion; volume ramp-up expected to reduce input cost drag
3 · End FY27 (Mar 2027)
Consumer Products breakeven target; membrane expansion (Mann & Hummel) plant commissioning in Goa
Valuation likely to remain under pressure until H2 demonstrates recovery.
Legacy Overrun Masks Order Strength—Recovery Hinges on Execution
Ion Exchange's ₹82.8 crore net loss stems from a ₹121.5 crore EBIT collapse in Treatment Solutions. But a resilient order book and 35% growth in Industrial Products suggest the quarter is more transitional than terminal.
₹674.7 Cr
-8.1% YoY
-₹82.8 Cr
-265.8% YoY
~₹121.5 Cr EBIT
Treatment Solutions overruns (≈90% of loss)
Mixed
Industrial +35%, Consumer -4.1 Cr EBIT
Where the profit came from
Ion Exchange's ₹82.8 crore net loss is not a story of operational collapse—it's a story of legacy contract cost overruns colliding with geopolitical headwinds. The Treatment Solutions segment, which was expected to be a stable cash generator, recorded a ₹121.5 crore EBIT loss in Q2 (vs. a ₹12.2 crore loss a year ago). Management attributes roughly 90% of the quarter's negative PAT to legacy project cost estimate revisions—meaning the organic business delivered a weaker but not disaster-level result. Strip that out and the company is managing through margin compression from input inflation and slower-than-expected ramp-up of its Roha specialty chemicals facility.
We have reached the bottom of the barrel as far as that is concerned. We have been talking for close to about 8 quarters in our calls.
Management's claims vs. what actually held up
Legacy project cost overruns fully accounted for in Q2
Treatment Solutions EBIT loss ₹121.5 Cr reflects ~90% of negative PBT; management confident no further material adverse impact
Supported
Strong ₹296.9 Cr order book will drive H2 recovery
Order book is real but Treatment Solutions revenue halved YoY despite it; execution weak, geopolitical deferral risk material
Overstated
Roha plant at 25% utilization, ramp-up progressing
25% utilization achieved in Q2; facility commissioned Sept 2025; backward integration in final commissioning phase. Management acknowledged softer than expected.
Supported but softer than guidance
Consumer Products on track for FY27 breakeven
H1 EBIT loss -₹4.5 Cr despite 32% revenue growth; management says marginally below expectations but still projects end-FY27 breakeven
Overstated
Industrial Products momentum will continue
Q2 revenue ₹136 Cr (+35% YoY), H1 +25% YoY; EBIT at ₹86 Cr (vs ₹74 Cr); order inflow ₹81.3 Cr in Q2 driven by medium-sized and Hyundai deal
Supported
What shifted on this call
The quarter confirmed three things: (1) Industrial Products is the only segment firing on all cylinders — 35% YoY growth with strong order momentum (₹81.3 Cr inflow in Q2 alone, including the Hyundai Engineering & Construction deal worth USD 52.83 Cr). (2) Treatment Solutions is in triage mode — revenue collapsed 49% YoY to ₹149.8 Cr as legacy projects matured, GCC region dispatches deferred due to Middle East crisis, and accounting reversals hit. Management claims the worst is behind, but execution risk remains high. (3) Specialty Chemicals is ramping but dragging margins — Roha facility now operational at only 25% utilization (softer than expected), with facility costs and West Asia input inflation each dragging margins by roughly 7%. Consumer Products, despite 32% H1 revenue growth, remains unprofitable (-₹4.1 Cr EBIT in Q2, -₹4.5 Cr H1).
Geopolitical headwinds are material. West Asia crisis is raising specialty chemical input costs by 7–8% and deferring GCC region Treatment Solutions dispatches to H2. Management is working on pricing pass-through (domestic market showing better acceptance), but the international pass-through remains incomplete. Government receivables are also a drag — roughly 10% of total receivables are Jal Jeevan Mission contracts where fund flow is slower than expected, forcing management to calibrate dispatch in proportion to funds received.
Industrial Products +35% YoY, strong order inflow of ₹81.3 Cr in Q2
Order book ₹296.9 Cr + bid pipeline ₹937 Cr provide multi-quarter visibility
Hyundai Engineering & Construction contract (USD 52.83 Cr) signals new revenue tier
Specialty Chemicals revenue +17% YoY despite margin drag
Consumer Products revenue +32% YoY H1; franchise model showing early traction
₹82.8 Cr loss driven by one-time legacy provisions (~90% of PAT); organic business weaker but not terminal
Legacy cost overruns suggest planning/estimation weakness, raising forward guidance credibility risk
Treatment Solutions revenue down 49% YoY despite ₹3,000 Cr order book — execution risk acute
Roha facility at softer 25% utilization; backward integration delays pushing margin recovery further out
Geopolitical deferral risk material (GCC dispatches delayed, input costs +7–8% unresolved)
Consumer Products breakeven target (FY27 end) remains aspirational; still loss-making despite 32% growth
Government receivable delays (~10% of total) creating cash flow headwind
Risks, ranked by how much they should concern a holder
Execution on Treatment Solutions order book conversion (geopolitical deferral ongoing)
High₹3,000 Cr order book is real, but Q2 revenue halved YoY despite it. Geopolitical deferral in GCC region means H2 ramp-up is not guaranteed. If execution slips, recovery narrative collapses.
Legacy contract cost estimation weakness (signal of forward-looking risk)
HighManagement's cost overruns took 8 quarters to materialize fully. This reduces confidence in near-term guidance on margins, ramp-ups, and consumer breakeven targets. Signal: planning discipline is weak.
Roha facility ramp-up remains slow (25% utilization, facility cost drag)
HighFacility commissioned Sept 2025 but only at 25% utilization in Q2. Backward integration still in final commissioning. Margin recovery timeline extends further; near-term drag persists.
West Asia input cost inflation unresolved (pricing pass-through incomplete)
High7–8% of Specialty Chemicals margin compression from West Asia crisis. Pricing pass-through in progress but international markets slower to accept. Further geopolitical escalation could widen margin pressure.
Consumer Products profitability timeline slipping (still loss-making despite growth)
Medium32% revenue growth in H1 but -₹4.5 Cr EBIT loss. FY27 end breakeven target appears aspirational. If profitability lags, segment burns capital longer, pressuring consolidated returns.
Government receivables and Jal Jeevan Mission fund flow delays
Medium~10% of receivables tied to govt. contracts with slower fund flow. Forcing dispatch calibration to available funds. Liquidity pressure if delays worsen.
How the street is positioned
The market confirmed the quarter's weakness and held skeptical. The stock fell 7.28% on day 1 (announcement day), extended losses to -10.34% by day 3, and recovered modestly to -2.58% by day 5. The move held lower — the market did not read the order book and Industrial strength as enough to offset legacy overruns and execution risk. That verdict aligns with the fundamental picture: a company in triage.
Valuation context: The stock trades at ₹322.5, a 58% discount to its all-time high of ₹768.4, and sits below all key moving averages (SMA20 ₹338.37, SMA50 ₹383.46, SMA200 ₹382.25). RSI at 37 is neutral—not oversold enough to signal a bounce, not rising enough to signal momentum. The stock is deeply beaten down but not yet attracting institutional buying.
Ownership data supports the cautious tone. FII holdings are stable at 4.86% (up a modest 23 bps QoQ from Q1 FY27), DII at 15.32% (up 52 bps), and promoter at 27.77% (down 11 bps). No institutional panic selling, but also no aggressive accumulation. Institutions are holding but watching—waiting for evidence of H2 execution before committing fresh capital. Promoter has trimmed marginally (11 bps), a sign of measured rebalancing rather than distress.
What to watch next
1 · Treatment Solutions H2 execution ramp
Does Hyundai contract delivery materialize as promised? Management would not quantify FY27 revenue from USD 52.83 Cr deal. GCC region dispatch cadence will reveal whether geopolitical deferral is truly temporary or structural.
2 · Roha facility backward integration and margin recovery
Completion of final commissioning phase targeted for FY27 end. Any delay pushes margin inflection further out. Pricing power and input cost pass-through gains are key — if margins remain compressed, the facility becomes a drag.
3 · Consumer Products path to breakeven
H1 loss of -₹4.5 Cr despite 32% growth raises questions about the breakeven target. Management says marginally below expectations, but the gap is material. Evidence of operating leverage (EBIT improvement per rupee of revenue) by H2 is the test.
This is steady-state recovery work, not a step-change. Ion Exchange has one solid business (Industrial Products, +35% YoY), one struggling business (Treatment Solutions, execution risk), and one growth story still proving its profitability thesis (Consumer Products). The order book is real, the geopolitical headwinds are real, and the cost inflation is real. None of these resolve immediately.
The stock is priced at 58% off its all-time high—a steep discount that reflects the market's skepticism of near-term recovery. That skepticism is justified until management demonstrates it can convert the order book into margin-accretive revenue despite geopolitical deferral and input inflation.
The single number to track from here is organic EBIT growth (adjusted for the legacy provision) in Q3. If H2 delivers improving EBIT despite flat or slightly declining revenue, the recovery narrative holds. If margins compress further or revenue remains depressed, the execution risk has materialized and the stock remains at risk of re-testing lower. The market is waiting for proof, not hope.